Compare GSK plc (GSK) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Nokia Corp — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Nokia Corp for 66 Days on average.
| GSK | NOK | |
|---|---|---|
Market Cap | $91.88B | $56.99B |
Volume | 7,730,529 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $61.18 | $16.83 |
52-Week Low | $43.24 | $5.18 |
Typical Hold Time | 93 Days | 66 Days |
Enterprise Value | $111.88B | $55.01B |
Dividend Yield | 3.9% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Nokia (NOK) trades at $10.36, down 2.45% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, with a beat in Q2 2026 but a miss in Q1 2026. Revenue for 2025 was $19.89 billion, with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation disconnect, with a high P/E of 75.09 but strong analyst optimism—61.5% recommend Buy, with a consensus price target of $17.50. Upside catalysts include AI infrastructure demand and strategic partnerships, while risks involve competitive pressures and volatile cash flows, evidenced by a net cash outflow of $1.16 billion in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
